* age less than 18 years * known allergy to vitamin c * inability to obtain consent from patient or next of kin * presence of diabetic ketoacidosis * any history of oxalate stones at any time * patients with kidney disease improving global outcomes (kdigo), ckd stage 4 (egfr \< 30 ml/min, ckd stage 5 and end-stage renal disease on dialysis patients are excluded. * patients with acute kidney injury, stage 3. * pregnant, or lactating * known diagnosis of glucose-6-phosphate dehydrogenase (g6pd) deficiency * patients who received the following medications within 7 days prior to enrollment, or plan to receive during enrollment, or 7 days after enrollment: aluminum hydroxide, bortezomib, copper, deferoxamine, amphetamines including derivatives such as fluphenazine. * patients with active sickle cell crisis * prisoners * patients outside icu level care

* age less than 18 years * known allergy to vitamin c * inability to obtain consent from patient or next of kin * presence of diabetic ketoacidosis * any history of oxalate stones at any time * patients with kidney disease improving global outcomes (kdigo), ckd stage 4 (egfr \< 30 ml/min, ckd stage 5 and end-stage renal disease on dialysis patients are excluded. * patients with acute kidney injury, stage 3. * pregnant, or lactating * known diagnosis of glucose-6-phosphate dehydrogenase (g6pd) deficiency * patients who received the following medications within 7 days prior to enrollment, or plan to receive during enrollment, or 7 days after enrollment: aluminum hydroxide, bortezomib, copper, deferoxamine, amphetamines including derivatives such as fluphenazine. * patients with active sickle cell crisis * prisoners * patients outside icu level care

age less than 18 years known allergy to vitamin c inability to obtain consent from patient or next of kin presence of diabetic ketoacidosis any history of oxalate stones at any time patients with kidney disease improving global outcomes (kdigo), ckd stage 4 (egfr < 30 ml/min, ckd stage 5 and end-stage renal disease on dialysis patients are excluded. patients with acute kidney injury, stage 3. pregnant, or lactating known diagnosis of glucose-6-phosphate dehydrogenase (g6pd) deficiency patients who received the following medications within 7 days prior to enrollment, or plan to receive during enrollment, or 7 days after enrollment: aluminum hydroxide, bortezomib, copper, deferoxamine, amphetamines including derivatives such as fluphenazine. patients with active sickle cell crisis prisoners patients outside icu level care

age less than 18 years known allergy to vitamin c inability to obtain consent from patient or next of kin presence of diabetic ketoacidosis any history of oxalate stones at any time patients with kidney disease improving global outcomes (kdigo), ckd stage 4 (egfr < 30 ml/min, ckd stage 5 and end-stage renal disease on dialysis patients are excluded. patients with acute kidney injury, stage 3. pregnant, or lactating known diagnosis of glucose-6-phosphate dehydrogenase (g6pd) deficiency patients who received the following medications within 7 days prior to enrollment, or plan to receive during enrollment, or 7 days after enrollment: aluminum hydroxide, bortezomib, copper, deferoxamine, amphetamines including derivatives such as fluphenazine. patients with active sickle cell crisis prisoners patients outside icu level care

- age less than 18 years - known allergy to vitamin c - inability to obtain consent from patient or next of kin - presence of diabetic ketoacidosis - any history of oxalate stones at any time - patients with kidney disease improving global outcomes (kdigo), ckd stage 4 (egfr < 30 ml/min, ckd stage 5 and end-stage renal disease on dialysis patients are excluded. - patients with acute kidney injury, stage 3 (see page 28). - pregnant, or lactating - known diagnosis of glucose-6-phosphate dehydrogenase (g6pd) deficiency - patients who received the following medications within 7 days prior to enrollment, or plan to receive during enrollment, or 7 days after enrollment: aluminum hydroxide, bortezomib, copper, deferoxamine, amphetamines including derivatives such as fluphenazine. - patients with active sickle cell crisis - prisoners

- age less than 18 years - known allergy to vitamin c - inability to obtain consent from patient or next of kin - presence of diabetic ketoacidosis - any history of oxalate stones at any time - patients with kidney disease improving global outcomes (kdigo), ckd stage 4 (egfr < 30 ml/min, ckd stage 5 and end-stage renal disease on dialysis patients are excluded. - patients with acute kidney injury, stage 3 (see page 28). - pregnant, or lactating - known diagnosis of glucose-6-phosphate dehydrogenase (g6pd) deficiency - patients who received the following medications within 7 days prior to enrollment, or plan to receive during enrollment, or 7 days after enrollment: aluminum hydroxide, bortezomib, copper, deferoxamine, amphetamines including derivatives such as fluphenazine. - patients with active sickle cell crisis - prisoners

- known allergy to vitamin c - inability to obtain consent from patient or next of kin - presence of diabetic ketoacidosis - active kidney stone(s) - pregnant - incarcerated

- known allergy to vitamin c - inability to obtain consent from patient or next of kin - presence of diabetic ketoacidosis - active kidney stone(s) - pregnant - incarcerated